Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
Status:
Not yet recruiting
Trial end date:
2037-05-01
Target enrollment:
Participant gender:
Summary
This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main
purpose of this study is to see if tirzepatide can reduce number of these participants who
require a knee replacement. Participants will be randomized to take a weekly injection of
tirzepatide or a placebo for a total of 72 weeks.